• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cencora Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    3/10/25 5:00:25 PM ET
    $COR
    Other Pharmaceuticals
    Health Care
    Get the next $COR alert in real time by email
    false 0001140859 0001140859 2025-03-06 2025-03-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 6, 2025

     

     

     

    Cencora, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Commission File Number: 1-6671

     

    Delaware   23-3079390
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)
             
    1 West First Avenue Conshohocken PA   19428-1800
    (Address of principal executive offices)   (Zip Code)

     

    (610) 727-7000

    (Registrant’s telephone number, including area code) 

     

    Not Applicable

    (Former name or former address, if changed since last report.)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of exchange on which registered
    Common stock COR New York Stock Exchange (NYSE)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company     ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ¨

     

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    (a)Cencora, Inc. (the “Company”) held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”) on March 6, 2025.

     

    (b)Each of the three items listed below was submitted to a vote of the Company's shareholders at the Annual Meeting and is described in more detail in the definitive proxy statement filed by the Company with the Securities and Exchange Commission on January 23, 2025 (the “Proxy Statement”). The final voting results are set forth below:

     

    Item 1 - Election of Directors.

     

    Each of the individuals listed below was elected by the Company’s shareholders.

     

    Nominees  For  Against  Abstentions  Broker Non-Votes 
    Ornella Barra   168,413,582   762,532   166,952   9,542,398 
    Werner Baumann   165,837,072   3,354,227   151,767   9,542,398 
    Frank K. Clyburn   167,730,172   1,458,056   154,838   9,542,398 
    Steven H. Collis   165,458,442   3,759,064   125,560   9,542,398 
    D. Mark Durcan   168,590,464   597,571   155,031   9,542,398 
    Lon R. Greenberg   153,366,924   15,673,799   302,343   9,542,398 
    Lorence H. Kim, M.D.   167,048,677   2,132,892   161,497   9,542,398 
    Robert P. Mauch   167,590,712   1,597,295   155,059   9,542,398 
    Redonda G. Miller, M.D.   164,014,442   5,165,281   163,343   9,542,398 
    Dennis M. Nally   166,267,786   2,918,693   156,587   9,542,398 
    Lauren M. Tyler   161,743,928   7,426,800   172,338   9,542,398 

     

    Item 2 - Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers.

     

    The Company’s shareholders approved this item. The voting results were as follows:

     

    For  Against  Abstentions  Broker Non-Votes 
     156,885,713   12,269,867   187,486   9,542,398 

     

    Item 3 - Ratification of Appointment of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2025.

     

    The Company’s shareholders approved this item. The voting results were as follows:

     

    For   Against   Abstentions   Broker Non-Votes  
    166,297,099   12,410,706    177,659     N/A  

     

    No item other than the three items addressed above and described in the Proxy Statement was submitted at the Annual Meeting for shareholder action.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Cencora, Inc.
       
    March 10, 2025 By: /s/ Elizabeth S. Campbell
        Name: Elizabeth S. Campbell
        Title: Executive Vice President and Chief Legal Officer

     

     

     

    Get the next $COR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COR

    DatePrice TargetRatingAnalyst
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    12/14/2023$213.00Equal Weight
    Wells Fargo
    12/14/2021$162.00 → $170.00Buy → Neutral
    Citigroup
    11/26/2021$136.00 → $170.00Sector Perform
    RBC Capital
    11/16/2021Underweight → Equal-Weight
    Barclays
    More analyst ratings

    $COR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho resumed coverage on Cencora with a new price target

      Mizuho resumed coverage of Cencora with a rating of Outperform and set a new price target of $280.00

      12/4/24 7:30:44 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora downgraded by BofA Securities with a new price target

      BofA Securities downgraded Cencora from Buy to Neutral and set a new price target of $245.00 from $275.00 previously

      9/18/24 8:27:47 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Leerink Partners initiated coverage on Cencora with a new price target

      Leerink Partners initiated coverage of Cencora with a rating of Outperform and set a new price target of $261.00

      2/26/24 7:28:01 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Nally Dennis M was granted 121 shares, increasing direct ownership by 0.92% to 13,251 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/5/25 4:07:07 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Director Baumann Werner was granted 125 shares, increasing direct ownership by 5% to 2,896 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/5/25 4:05:32 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Director Tyler Lauren M was granted 104 shares, increasing direct ownership by 4% to 2,875 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/5/25 4:03:54 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/29/24 4:02:27 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Financials

    Live finance-specific insights

    See more
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

      3/28/25 7:00:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

      Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional

      2/6/25 8:30:00 PM ET
      $COR
      $WBA
      Other Pharmaceuticals
      Health Care
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $COR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

      3/28/25 7:00:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

      Cencora, Inc. (NYSE:COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance's sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended. Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The concurrent share repurchase will be made under Cencora's share repurchase program and the repurchased shares will be held in treasury. The sale of Cencora shares by Walgreens Boots Alliance is occurring simultaneously with the early set

      2/6/25 8:37:00 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Leadership Updates

    Live Leadership Updates

    See more
    • Cencora Expands Enterprise Leadership Team with Two Senior Appointments

      Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

      11/4/24 8:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Network Wireless Solutions (NWS) Appoints Michael Millegan to Board of Directors

      The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo

      9/14/21 2:00:00 PM ET
      $AXS
      $COR
      $POR
      $WTT
      Property-Casualty Insurers
      Finance
      Other Pharmaceuticals
      Health Care

    $COR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cencora Inc.

      SC 13G/A - Cencora, Inc. (0001140859) (Subject)

      11/14/24 1:22:34 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cencora Inc.

      SC 13D/A - Cencora, Inc. (0001140859) (Subject)

      8/5/24 6:43:49 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by CoreSite Realty Corporation (Amendment)

      SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)

      7/12/21 8:29:18 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cencora Inc.

      10-Q - Cencora, Inc. (0001140859) (Filer)

      5/7/25 1:48:31 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cencora, Inc. (0001140859) (Filer)

      5/7/25 6:36:20 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cencora, Inc. (0001140859) (Filer)

      3/10/25 5:00:25 PM ET
      $COR
      Other Pharmaceuticals
      Health Care